New cell therapy trial aims to tame rare autoimmune disease

NCT ID NCT07061938

Recruiting now Disease control Sponsor: Acepodia Biotech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment called ACE1831 for people with IgG4-related disease, a rare condition where the immune system attacks the body, causing swelling and organ damage. ACE1831 is made from healthy donor cells and given as an infusion. The study will check if it is safe and can help control the disease. About 30 adults with active disease will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGG4-RELATED DISEASE

Contacts and locations

Locations

Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Kanazawa Medical University Hospital
RECRUITING

Kahoku-gun, JP, 920-0293, Japan
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.